Trials / Active Not Recruiting
Active Not RecruitingNCT05879822
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB099280 | Administered as specified in the treatment arm description |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2026-07-22
- Completion
- 2026-07-22
- First posted
- 2023-05-30
- Last updated
- 2025-12-17
Locations
54 sites across 9 countries: Brazil, China, Georgia, Greece, Hungary, New Zealand, Romania, South Africa, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05879822. Inclusion in this directory is not an endorsement.